JAZZ NASDAQ
Jazz Pharmaceuticals plc
1W: -3.3%
1M: -13.2%
3M: -19.2%
YTD: +19.4%
1Y: +49.3%
3Y: +54.8%
5Y: +43.6%
$206.78
+1.08 (+0.53%)
Pre-Market: $210.73 (+3.95, +1.91%)
Weekly Expected Move ±3.7%
$198
$206
$214
$222
$230
Credit Risk of going bust: lower than 57% of companies Debt: 24.7% of company value Bonds: $459.8M held by 158 funds, 99 bp over Treasuries → details ▾
If the stock fell to about $5.81 (down 97%), Jazz Pharmaceuticals plc would be worth roughly what it owes.
Total debt $4.41B against a stock market value of $13.42B.
Distance to default 5.85 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.68B (short-term plus half of long-term), stock volatility 36.3%; Altman Z'' 2.72. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Total debt $4.41B against a stock market value of $13.42B.
Distance to default 5.85 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.68B (short-term plus half of long-term), stock volatility 36.3%; Altman Z'' 2.72. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
12 relationships9
As Filer
counterparties named
3
As Counterparty
mentioned by others
3
Rel. Types
2021-04-20
Earliest Filing
2025-03-05
Latest Filing
target: 4
partner: 3
acquirer: 2
Counterparties (Filed by JAZZ)
9 relationshipsCompanies named in JAZZ's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Chimerix, Inc. | — | target | Target of a merger and tender offer by Jazz Pharmaceuticals via Pinetree Acquisition Sub, Inc. | 2025-03-05 | View |
| Pinetree Acquisition Sub, Inc. | — | acquirer | Wholly owned indirect subsidiary of Jazz Pharmaceuticals entering into a merger agreement to acquire Chimerix, Inc. | 2025-03-05 | View |
| Zymeworks BC Inc. | ZYME | partner | Partner in License and Collaboration Agreement for zanidatamab development and commercialization | 2022-12-05 | View |
| Zymeworks Inc. | ZYME | partner | Parent company of Zymeworks BC Inc. | 2022-12-05 | View |
| BeiGene, Ltd. | — | partner | Company to which Zymeworks previously licensed certain Asia/Pacific territories | 2022-12-05 | View |
| GW Pharmaceuticals plc | — | target | Target company acquired by Jazz Pharmaceuticals in a scheme of arrangement | 2021-05-05 | View |
| Jazz Pharmaceuticals UK Holdings Limited | JAZZ | acquirer | Bidco entity incorporated in England and Wales that acquired GW Pharmaceuticals | 2021-05-05 | View |
| GW Pharmaceuticals plc | — | target | Target of the proposed acquisition by Jazz Pharmaceuticals. | 2021-04-29 | View |
| GW Pharmaceuticals PLC | — | target | Target company in the proposed acquisition by Jazz Pharmaceuticals. | 2021-04-20 | View |
Mentioned As Counterparty
3 mentionsOther companies that named JAZZ in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| ZYME Zymeworks Inc. | partner | Parent company of Jazz Pharmaceuticals Ireland Limited and Jazz Inc., entered into an amended collaboration agreement an | 2023-05-16 | View |
| AXSM Axsome Therapeutics, Inc. | customer | Axsome Therapeutics acquired worldwide rights to Sunosi (excluding twelve Asian markets) from Jazz Pharmaceuticals. | 2022-11-14 | View |
| AXSM Axsome Therapeutics, Inc. | acquirer | Seller of Sunosi assets to Axsome Therapeutics | 2022-03-28 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-26 | Earnings Release | View | |
| 2026-10-09 | Officer/Director Change | View | |
| 2026-09-23 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-09-15 | Regulation FD | View | |
| 2026-08-31 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-08-25 | Other Events | View | |
| 2026-08-10 | Regulation FD; Exhibits | View | |
| 2026-08-10 | Material Agreement; Exhibits | Agreement | View |
| 2026-08-03 | Earnings Release; Exhibits | View | |
| 2026-07-24 | Shareholder Vote | View | |
| 2026-05-29 | Officer/Director Change | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-17 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-28 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-22 | Other Events | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-25 | Submission of Matters to a Vote of Security Holders | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR